| Abnormal involuntary movement scale, 175-176 |
| Absorbent products, 217 |
| Accident prevention. See Safety/accident prevention |
| Acetylcholine, 18, 184 |
| Acetylcholine precursors, 184 |
| Acetylcholine releasers, 185 |
| Acetyl-L-carnitine, 192 |
| Activities of daily living. See Daily care |
| Activity. See also Treatment programs
importance of, 148 |
| Adult day care, 357 |
| |
| Adult foster homes, 361 |
| Advance directives, 288, 297-298 |
| | durable power of attorney for health care,
297, 307-311 | | living will, 297-298, 311-312 |
|
| Ageism, 329 |
| Aggressive behavior, 157-158 |
| | drugs and, 178 | | restraints and, 238 |
|
| Agitated behavior, 157 |
| | bathing and, 248 | | restraints and, 238 |
|
| Agnosia, 78 |
| AIDS, 100 |
| |
| Alcohol, 114 |
| | in differential diagnosis, 90, 97-98 |
|
| Alcohol-induced dementia, 133-134 |
| Alpha-glycerylphosphorylcholine, 121 |
| Alzheimer's Association, 87, 365 |
| | advocacy by, 375 | | mission of, 368 | | national partnerships to improve Alzheimer's
disease care, 372-373 | | national project grants to chapters, 372 | | organization of, 367-368 | | origins of, 367 | | patient and family services, 371-373 | | professional education programming, 374‐
375 | | public awareness and education, 373-374 | | Reagan institute initiative, 371 | | research activities of, 368-371 | | safe return program, 372 | | support groups, 371 | | Zenith Awards, 370 |
|
| Alzheimer's disease |
| | clinical manifestations, 3 | | diagnosis for, 3-4 | | discovery of, 55-56 | | economic implications of, 2 | | etiology of, 3 | | false positive for, 31-32 |
|
| Alzheimer's disease—cont'd |
| | historical perspective of, 53-58 | | incidence of, 57-58 | | information on, 344-346 | | vs. multiinfarct dementia, 30-31 | | prevalence of, 1-2 | | risk factors and potential protective factors, 69 | | sequence of disruption and most distinguishing cognitive features, 30, 31 |
|
| Alzheimer's Disease Education and Referral
Centers, 343 |
| Alzheimer, Alois, 54-56 |
| Amitriptyline, 178, 179 |
| Amygdala, 23 |
| Amyloid, 61-62 |
| Angiotension converting enzyme inhibitors, 192 |
| Anomia, 77 |
| Antidepressants, 178-181 |
| |
| Antioxidant drug therapy, 188 |
| Antipsychotic drugs, 19, 172-177 |
| |
| Anxiety, meaning of, 261 |
| Anxiolytics, 177-178 |
| Apathy, 164-165 |
| Aphasia, 78 |
| Apraxia, 78-79 |
| Area Agency on Aging, 354-355 |
| Aricept, 4, 186-187 |
| Arrhythmias, 107-108 |
| Arteriosclerosis, 100 |
| Aspirin, 120 |
| Assessment |
| | terminal care and, 276-278 | | in treatment program, 269 |
|
| Assisted living, 360 |
| Basal ganglia, 22-23 |
| Basal nucleus of Meynert, 15, 16 |
| | Alzheimer's disease and, 16, 18-19 |
|
| Bathing, 246-248 |
| | causes for difficulty in, 246 | | frequency of, 247 | | hair care, 247-248 | | handling agitation, 248 | | routines for, 246-247 | | safety and, 230, 247 | | terminal care and, 277 | | useful strategies for, 248 |
|
| Beck Depression Inventory, 33 |
| Bedpans, 216-217 |
| Behavior, difficult, 80-81 |
| | aggression and combativeness, 157-158 | | agitation and restlessness, 157 | | analysis of, 261 |
|
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset